Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vir Biotechnology Inc Market Cap
The Vir Biotechnology Inc (VIR) share price is expected to increase by 337.47% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered VIR. Price targets range from $15 at the low end to $110 at the high end. The current analyst consensus for VIR is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Vir Biotechnology Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Vir Biotechnology Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of VIR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Aug 20, 2024 |
| Gena Wang Barclays | Overweight | $28 | Maintains | Aug 2, 2024 |
| Michelle Gilson Morgan Stanley | Equal-Weight | $15 | Maintains | Jun 6, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Jun 5, 2024 |
| Joseph Stringer Needham | Buy | $19 | Maintains | Jun 5, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 24, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | May 7, 2024 |
| Eric Joseph JP Morgan | Neutral | $12 | Maintains | May 3, 2024 |
| Joseph Stringer Needham | Buy | $15 | Reiterates | May 3, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Reiterates | Mar 15, 2024 |
| Eric Joseph JP Morgan | Neutral | $10 | Maintains | Feb 23, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $110 | Maintains | Feb 14, 2024 |
| Eric Joseph JP Morgan | Neutral | $9 | Downgrade | Jan 29, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $85 | Maintains | Jan 23, 2024 |
| Joseph Stringer Needham | Buy | $15 | Maintains | Nov 3, 2023 |
| Geoff Meacham B of A Securities | Neutral | $14 | Downgrade | Sep 8, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $95 | Maintains | Aug 7, 2023 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | Aug 4, 2023 |
| Gena Wang Barclays | Overweight | $41 | Maintains | Jul 21, 2023 |
| Michelle Gilson Morgan Stanley | Equal-Weight | $15 | Maintains | Jul 21, 2023 |
When did it IPO
2019
Staff Count
587
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Market Cap
$1.06B
In 2023, VIR generated $39.5M in revenue, which was a decrease of -97.50% from the previous year. This can be seen as a signal that VIR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology Inc. appointed Jason O'Byrne as Executive Vice President and CFO, effective October 2, 2024. He brings over 20 years of finance and operations experience.
Why It Matters - The appointment of a seasoned CFO can enhance financial strategy and operational efficiency at Vir Biotechnology, potentially impacting stock performance and investor confidence.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology has completed its exclusive license agreement with Sanofi for three clinical-stage T-cell engagers, enabling potential applications in cancer treatment.
Why It Matters - The closure of the licensing agreement boosts Vir Biotechnology's pipeline, potentially enhancing its market position and revenue from innovative cancer therapies, impacting stock performance.
Thu, 22 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Vir Biotechnology CEO Marianne De Backer will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 5 at 1:50 p.m. PT. A webcast will be available on the company's website.
Why It Matters - Marianne De Backer's participation in a major healthcare conference can signal potential strategic insights and future directions for Vir Biotechnology, impacting investor sentiment and stock performance.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - 24/7 Wall Street
Summary - Market pullbacks may deter investors from speculative industries, according to 24/7 Wall St. Insights.
Why It Matters - Market pullbacks can lead to increased caution among investors, potentially driving down demand and valuations in speculative industries, affecting investment strategies and portfolio performance.
Tue, 06 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Vir Biotechnology (VIR) has a consensus price target indicating a potential upside of 258.4%. Upward revisions in earnings estimates suggest possible near-term stock gains.
Why It Matters - A 258.4% upside potential indicates strong growth expectations for Vir Biotechnology (VIR), while rising earnings estimates suggest possible near-term stock price increases.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Vir Biotechnology, Inc. (NASDAQ:VIR) will host its Q2 2024 Earnings Conference Call on August 1, 2024, at 4:30 PM ET, featuring key executives and analysts from major firms.
Why It Matters - The earnings call provides insights into Vir Biotechnology's financial health and strategic direction, influencing investor sentiment and stock performance. Key participants indicate potential market impact and analysis.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
